Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Sold by Signet Financial Management LLC

Signet Financial Management LLC trimmed its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 26.2% during the fourth quarter, Holdings Channel reports. The firm owned 9,940 shares of the specialty pharmaceutical company’s stock after selling 3,521 shares during the period. Signet Financial Management LLC’s holdings in Jazz Pharmaceuticals were worth $1,223,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in JAZZ. US Bancorp DE increased its position in Jazz Pharmaceuticals by 13.3% in the 1st quarter. US Bancorp DE now owns 2,736 shares of the specialty pharmaceutical company’s stock valued at $427,000 after acquiring an additional 322 shares during the period. Private Advisor Group LLC acquired a new stake in Jazz Pharmaceuticals in the 1st quarter valued at approximately $547,000. Aviva PLC increased its position in Jazz Pharmaceuticals by 87.1% in the 1st quarter. Aviva PLC now owns 40,005 shares of the specialty pharmaceutical company’s stock valued at $6,228,000 after acquiring an additional 18,628 shares during the period. Allianz Asset Management GmbH increased its position in Jazz Pharmaceuticals by 118.2% in the 1st quarter. Allianz Asset Management GmbH now owns 12,130 shares of the specialty pharmaceutical company’s stock valued at $1,888,000 after acquiring an additional 6,571 shares during the period. Finally, Vanguard Group Inc. increased its position in Jazz Pharmaceuticals by 1.0% in the 1st quarter. Vanguard Group Inc. now owns 5,602,650 shares of the specialty pharmaceutical company’s stock valued at $872,164,000 after acquiring an additional 57,949 shares during the period. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Stock Performance

JAZZ opened at $108.90 on Wednesday. The firm has a market cap of $6.86 billion, a PE ratio of 17.79, a P/E/G ratio of 1.53 and a beta of 0.59. The company has a quick ratio of 1.85, a current ratio of 2.24 and a debt-to-equity ratio of 1.37. The business has a fifty day simple moving average of $120.99 and a 200-day simple moving average of $122.95. Jazz Pharmaceuticals plc has a fifty-two week low of $108.75 and a fifty-two week high of $146.70.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings data on Wednesday, February 28th. The specialty pharmaceutical company reported $4.40 earnings per share for the quarter, missing the consensus estimate of $4.44 by ($0.04). The company had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1.01 billion. Jazz Pharmaceuticals had a return on equity of 31.27% and a net margin of 10.82%. As a group, equities analysts predict that Jazz Pharmaceuticals plc will post 16.24 EPS for the current fiscal year.

Insider Transactions at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CFO Philip L. Johnson bought 12,000 shares of the firm’s stock in a transaction dated Friday, March 1st. The stock was acquired at an average price of $119.65 per share, with a total value of $1,435,800.00. Following the completion of the transaction, the chief financial officer now directly owns 27,932 shares in the company, valued at approximately $3,342,063.80. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other Jazz Pharmaceuticals news, CFO Philip L. Johnson bought 12,000 shares of the firm’s stock in a transaction dated Friday, March 1st. The stock was acquired at an average price of $119.65 per share, with a total value of $1,435,800.00. Following the completion of the transaction, the chief financial officer now directly owns 27,932 shares in the company, valued at approximately $3,342,063.80. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CAO Patricia Carr sold 1,936 shares of the firm’s stock in a transaction on Wednesday, March 6th. The stock was sold at an average price of $119.64, for a total value of $231,623.04. Following the completion of the sale, the chief accounting officer now directly owns 8,364 shares of the company’s stock, valued at approximately $1,000,668.96. The disclosure for this sale can be found here. 4.40% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several analysts recently commented on JAZZ shares. Royal Bank of Canada restated an “outperform” rating and issued a $195.00 target price on shares of Jazz Pharmaceuticals in a research report on Thursday, February 29th. HC Wainwright decreased their price target on Jazz Pharmaceuticals from $204.00 to $200.00 and set a “buy” rating for the company in a research note on Thursday, March 14th. Barclays decreased their price target on Jazz Pharmaceuticals from $235.00 to $230.00 and set an “overweight” rating for the company in a research note on Friday, March 1st. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $180.00 price target on shares of Jazz Pharmaceuticals in a research note on Wednesday, April 10th. Finally, Truist Financial reaffirmed a “buy” rating and set a $200.00 price target on shares of Jazz Pharmaceuticals in a research note on Wednesday, March 20th. Two analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Jazz Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $195.08.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.